94 related articles for article (PubMed ID: 17487373)
1. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
Rayburn ER; Wang W; Zhang R; Wang H
Int J Oncol; 2007 Jun; 30(6):1511-9. PubMed ID: 17487373
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.
Chiron D; Pellat-Deceunynck C; Maillasson M; Bataille R; Jego G
J Immunol; 2009 Oct; 183(7):4371-7. PubMed ID: 19734228
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.
Krieg AM
Oncogene; 2008 Jan; 27(2):161-7. PubMed ID: 18176597
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
Vollmer J; Krieg AM
Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
[TBL] [Abstract][Full Text] [Related]
6. Onopordum cynarocephalum induces apoptosis and protects against 1,2 dimethylhydrazine-induced colon cancer.
El-Najjar N; Saliba N; Talhouk S; Gali-Muhtasib H
Oncol Rep; 2007 Jun; 17(6):1517-23. PubMed ID: 17487413
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
[TBL] [Abstract][Full Text] [Related]
8. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
9. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
10. TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects.
Sommariva M; De Cecco L; De Cesare M; Sfondrini L; Ménard S; Melani C; Delia D; Zaffaroni N; Pratesi G; Uva V; Tagliabue E; Balsari A
Cancer Res; 2011 Oct; 71(20):6382-90. PubMed ID: 21878529
[TBL] [Abstract][Full Text] [Related]
11. Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer.
Tu S; Wai-Yin Sun R; Lin MC; Tao Cui J; Zou B; Gu Q; Kung HF; Che CM; Wong BC
Cancer; 2009 Oct; 115(19):4459-69. PubMed ID: 19572413
[TBL] [Abstract][Full Text] [Related]
12. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
[TBL] [Abstract][Full Text] [Related]
13. Human lung cancer cells express functionally active Toll-like receptor 9.
Droemann D; Albrecht D; Gerdes J; Ulmer AJ; Branscheid D; Vollmer E; Dalhoff K; Zabel P; Goldmann T
Respir Res; 2005 Jan; 6(1):1. PubMed ID: 15631627
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.
Ilvesaro JM; Merrell MA; Li L; Wakchoure S; Graves D; Brooks S; Rahko E; Jukkola-Vuorinen A; Vuopala KS; Harris KW; Selander KS
Mol Cancer Res; 2008 Oct; 6(10):1534-43. PubMed ID: 18922969
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine inhibits colon cancer cell growth in vitro and tumor growth in vivo via induction of apoptosis.
Zheng Y; Zhao YL; Deng X; Yang S; Mao Y; Li Z; Jiang P; Zhao X; Wei Y
Cancer Invest; 2009 Mar; 27(3):286-92. PubMed ID: 19194831
[TBL] [Abstract][Full Text] [Related]
16. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
[TBL] [Abstract][Full Text] [Related]
17. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
Jurk M; Kritzler A; Debelak H; Vollmer J; Krieg AM; Uhlmann E
ChemMedChem; 2006 Sep; 1(9):1007-14. PubMed ID: 16952134
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U; Scheulen ME; von Bergwelt-Baildon MS; Weihrauch MR
Expert Opin Investig Drugs; 2011 Mar; 20(3):361-72. PubMed ID: 21254877
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.
Melstrom LG; Bentrem DJ; Salabat MR; Kennedy TJ; Ding XZ; Strouch M; Rao SM; Witt RC; Ternent CA; Talamonti MS; Bell RH; Adrian TA
Clin Cancer Res; 2008 Oct; 14(20):6525-30. PubMed ID: 18927292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
